论文部分内容阅读
目的:评估自体DC-CIK细胞联合化疗用于晚期胃癌患者的疗效、生活质量及安全性。方法:收集2012年6月至2015年12月在兰州大学第一医院肿瘤内科住院并接受DC-CIK细胞联合化疗治疗的晚期胃癌患者70例为联合组。另外选取同期临床情况相似,仅进行化疗的晚期胃癌患者70例为对照组。观察两组的有效率、疾病控制率、无进展生存时间及总生存时间,评价其毒性反应发生情况,并分析两组患者治疗前后的生活质量改善情况。结果:联合组和对照组治疗的有效率分别为37.8%和29.5%(P>0.05),疾病控制率为80.0%和59.1%(P<0.05),无进展生存期为7.0和5.0个月(HR 0.62,95%CI 0.41~0.92,P<0.05),中位生存期为13.0个月和10.8个月(HR 0.68,95%CI 0.45~1.02,P>0.05);与对照组相比,联合组化疗前后生活质量未见明显下降;未见DC-CIK细胞相关严重不良事件发生。结论:自体DC-CIK细胞联合化疗治疗晚期胃癌在有效率、疾病控制率、生存期及生活质量等方面获得了一定的收益,无严重不良事件发生。
OBJECTIVE: To evaluate the efficacy, quality of life and safety of autologous DC-CIK cells combined with chemotherapy for patients with advanced gastric cancer. Methods: Seventy patients with advanced gastric cancer hospitalized from June 2012 to December 2015 in Department of Oncology, Lanzhou University First Hospital and received DC-CIK combined with chemotherapy were enrolled in the study. In addition to select the same period clinical similarities, only chemotherapy for advanced gastric cancer in 70 patients as control group. The effective rate, disease control rate, progression-free survival time and total survival time of the two groups were observed, and the occurrence of toxicity was evaluated. The quality of life before and after treatment was analyzed in both groups. Results: The effective rates of treatment in combination group and control group were 37.8% and 29.5% (P> 0.05), disease control rates were 80.0% and 59.1% (P <0.05), progression-free survival was 7.0 and 5.0 months HR 0.62, 95% CI 0.41-0.92, P <0.05). The median survival time was 13.0 months and 10.8 months (HR 0.68, 95% CI 0.45-1.02, P> 0.05). Compared with the control group, Quality of life before and after chemotherapy group no significant decline; no serious DC-CIK cell-related adverse events. Conclusion: The combination of autologous DC-CIK cells and chemotherapy in the treatment of advanced gastric cancer has obtained certain benefits in efficiency, disease control rate, survival and quality of life, and no serious adverse events occurred.